(Reuters) – Sanofi SA and partner Regeneron Pharmaceuticals Inc have started a clinical trial of their rheumatoid arthritis drug Kevzara as a treatment for the coronavirus, the companies said on Monday.
Enrolments for the mid-to-late stage trial will begin immediately, and the companies anticipate the trial will test up to 400 patients.
Kevzara is an infection-fighting protein known as monoclonal antibody.
Regeneron in February announced a partnership with the U.S. Department of Health and Human Services to develop a coronavirus treatment, and had said it would focus on monoclonal antibodies.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
